Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of PfSPZ-GA1 Malaria Vaccine in Healthy Volunteers
NCT03163121Phase 1Completed
- Sponsor
- Sanaria Inc.
- Start
- May 2017
- Primary completion
- Oct 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PfSPZ-GA1 in malaria (7 arms), sponsored by Sanaria Inc. Primary endpoints: Presence of blood stage parasites after inoculation with PfSPZ-GA1 Vaccine in Stage A at 28 days and Frequency and magnitude of adverse events in study groups in Stage A and B at 17 months. Started May 2017; status: completed.
02
Drugs
PfSPZ-GA1
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03163121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03163121.